<p>隨着全球市場的反彈，澳大利亞證券交易所（ASX）在九月份通常的熊市趨勢中表現出韌性，受到近期降息和主要金融機構經濟信號的提振。在這種背景下，儘管 “便士股票” 這一術語有些過時，但仍然為希望探索具有增長潛力的小型或新興公司的投資者提供了有趣的機會。雖然這些股票通常伴隨風險，但那些財務健康狀況良好的公司可以提供顯著的上行潛力，使其在當今市場環境中值得關注。</p>
<h3>澳大利亞十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.49</td>
<td>A$140.43M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.18</td>
<td>A$102.84M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.815</td>
<td>A$50.75M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.67</td>
<td>A$412.55M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.50</td>
<td>A$258.32M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Pureprofile (ASX:PPL)</td>
<td>A$0.043</td>
<td>A$50.3M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.075</td>
<td>A$38.83M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.76</td>
<td>A$363.06M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.30</td>
<td>A$1.41B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們 ASX 便士股票篩選器中的 427 只股票的完整列表。</p>
<p>讓我們探索篩選結果中的幾個突出選項。</p>
<h2>Archer Materials (ASX:AXE)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Archer Materials Limited 是一家專注於開發和商業化半導體設備和傳感器的科技公司，涉及量子計算、醫療診斷、TMR 傳感器和實驗室芯片技術，市值為 A$75.18 百萬。</p>
<p><strong>運營：</strong> 該公司從其材料技術研發部門產生的收入為 A$2.06 百萬。</p>
<p><strong>市值：</strong> A$75.18M</p>
<p>Archer Materials Limited 是一家半導體領域的科技公司，預計在 2025 年 6 月結束的財年報告收入為 A$2.8 百萬。儘管處於虧損狀態，淨虧損為 A$6.97 百萬，但通過無債務狀態和基於當前自由現金流超過三年的充足現金流保持財務穩定。公司的短期資產顯著超過其負債，表明流動性管理良好。然而，過去五年中，收益年均下降 10.1%，近期股東稀釋情況較少，周波動性穩定在 10%。</p>
<ul>
<li>在我們的財務健康報告中更詳細地瞭解 Archer Materials 的潛力。</li>
<li>探索歷史數據，以跟蹤 Archer Materials 隨時間的表現，在我們的過去結果報告中。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9020cb3c-7ddc-42da-92a4-c32aac24964a/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9020cb3c-7ddc-42da-92a4-c32aac24964a/chart/financial-position-analysis"/></p>
<p>ASX:AXE 財務狀況分析截至 2025 年 9 月</p>
<h2>Peet (ASX:PPC)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Peet Limited 在澳大利亞收購、開發和銷售住宅用地，市值為 A$833.32 百萬。</p>
<p><strong>運營：</strong> 公司的收入來自資金管理（A$56.39 百萬）、聯合安排（A$51.88 百萬）和公司自有項目（A$313.24 百萬）。</p>
<p><strong>市值：</strong> A$833.32M</p>
<p>Peet Limited 在過去一年中表現出強勁的財務增長，收益增長了 60%，超過了其五年平均水平和行業基準。公司的淨利潤率有所改善，得益於嚴格的戰略方法和澳大利亞住宅房地產市場的有利條件。儘管債務水平較高，Peet 的利息支付由 EBIT 良好覆蓋，表明財務義務可控。該公司目前正在進行由高盛主導的戰略審查，以優化其資產基礎並進一步利用市場機會。近期的股息增加反映了 Peet 在穩定的周波動性中回饋股東的承諾。</p>
<ul>
<li>點擊探索我們在 Peet 財務健康報告中的詳細發現。</li>
<li>查看我們的歷史業績報告，以獲取 Peet 的業績記錄的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/financial-position-analysis"/></p>
<p>ASX:PPC 財務狀況分析截至 2025 年 9 月</p>
<h2>XRF Scientific (ASX:XRF)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> XRF Scientific Limited 在澳大利亞、加拿大和歐洲製造和銷售貴金屬產品、專業化學品和儀器，服務於科學、分析、建築材料和礦業行業，市值為 A$306.01 百萬。</p>
<p><strong>運營：</strong> 公司的收入來自三個主要部門：消耗品（A$19.26 百萬）、貴金屬（A$21.51 百萬）和資本設備（A$22.56 百萬）。</p>
<p><strong>市值：</strong> A$306.01M</p>
<p>XRF Scientific Limited 在過去五年中表現出穩定的財務表現，收益年均增長 20.3%，儘管最近的增長 16.9% 未能超過行業平均水平。該公司保持強勁的資產負債表，短期資產顯著超過長期和短期負債，且債務由經營現金流良好覆蓋。儘管近期內部人士大量拋售，XRF 的管理層和董事會經驗豐富，任期平均超過 12 年。最近被納入 S&amp;P 全球 BMI 指數和股息增加表明市場情緒積極，淨利潤率較去年有所改善。</p>
<ul>
<li>在這裏深入瞭解 XRF Scientific 的詳細資產負債表健康報告。</li>
<li>在這裏瞭解 XRF Scientific 的未來增長軌跡。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 9 月 ASX:XRF 的債務與股本歷史及分析</p>
<h2>利用機會</h2>
<ul>
<li>點擊這裏解鎖我們全面的 427 只 ASX 便士股票列表。</li>
<li>尋找新視角？超越巨頭：這 24 只早期 AI 股票可能為您的退休提供資金。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

<p>ASX 在全球市場反彈中展現出韌性，低價股提供了引人注目的投資機會。市值低於 9 億澳元的顯著股票包括 Alfabs Australia（1.4043 億澳元）、EZZ Life Science Holdings（1.0284 億澳元）和 Dusk Group（5075 萬澳元）。Archer Materials（7518 萬澳元）專注於半導體技術，但仍處於無收入階段。Peet Limited（8.3332 億澳元）實現了 60% 的盈利增長，而 XRF Scientific（3.0601 億澳元）則保持強勁的財務健康，持續增長。鼓勵投資者在當前市場環境中探索這些選項</p>

<p>As global markets rally, the ASX has shown resilience against September's usual bearish trends, buoyed by recent rate cuts and economic signals from major financial institutions. In this context, penny stocks—though a somewhat outdated term—continue to offer intriguing opportunities for investors looking to explore smaller or newer companies with growth potential. While these stocks often come with risks, those backed by strong financial health can provide significant upside potential, making them worth watching in today's market landscape.</p>
<div class="lb-trans"><p>隨着全球市場的反彈，澳大利亞證券交易所（ASX）在九月份通常的熊市趨勢中表現出韌性，受到近期降息和主要金融機構經濟信號的提振。在這種背景下，儘管 “便士股票” 這一術語有些過時，但仍然為希望探索具有增長潛力的小型或新興公司的投資者提供了有趣的機會。雖然這些股票通常伴隨風險，但那些財務健康狀況良好的公司可以提供顯著的上行潛力，使其在當今市場環境中值得關注。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亞十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.49</td>
<td>A$140.43M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.18</td>
<td>A$102.84M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.815</td>
<td>A$50.75M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.67</td>
<td>A$412.55M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.50</td>
<td>A$258.32M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Pureprofile (ASX:PPL)</td>
<td>A$0.043</td>
<td>A$50.3M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.075</td>
<td>A$38.83M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.76</td>
<td>A$363.06M</td>
<td>✅ 5 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.30</td>
<td>A$1.41B</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Alfabs Australia (ASX:AAL)</td>
<td>A$0.49</td>
<td>A$140.43M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.18</td>
<td>A$102.84M</td>
<td>✅ 3 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Dusk Group (ASX:DSK)</td>
<td>A$0.815</td>
<td>A$50.75M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$2.67</td>
<td>A$412.55M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>MotorCycle Holdings (ASX:MTO)</td>
<td>A$3.50</td>
<td>A$258.32M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Pureprofile (ASX:PPL)</td>
<td>A$0.043</td>
<td>A$50.3M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Veris (ASX:VRS)</td>
<td>A$0.075</td>
<td>A$38.83M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$3.04</td>
<td>A$3.47B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Praemium (ASX:PPS)</td>
<td>A$0.76</td>
<td>A$363.06M</td>
<td>✅ 5 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Service Stream (ASX:SSM)</td>
<td>A$2.30</td>
<td>A$1.41B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 427 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們 ASX 便士股票篩選器中的 427 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>讓我們探索篩選結果中的幾個突出選項。</p>
</div><h2>Archer Materials (ASX:AXE)</h2>
<div class="lb-trans"><h2>Archer Materials (ASX:AXE)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Archer Materials Limited is a technology company focused on developing and commercializing semiconductor devices and sensors for quantum computing, medical diagnostics, TMR sensors, and lab-on-a-chip technologies in Australia, with a market cap of A$75.18 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Archer Materials Limited 是一家專注於開發和商業化半導體設備和傳感器的科技公司，涉及量子計算、醫療診斷、TMR 傳感器和實驗室芯片技術，市值為 A$75.18 百萬。</p>
</div><p><strong>Operations:</strong> The company generates revenue of A$2.06 million from its Materials Technology Research and Development segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其材料技術研發部門產生的收入為 A$2.06 百萬。</p>
</div><p><strong>Market Cap:</strong> A$75.18M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$75.18M</p>
</div><p>Archer Materials Limited, a technology company in the semiconductor sector, remains pre-revenue with A$2.8 million reported for the year ending June 2025. Despite being unprofitable, with a net loss of A$6.97 million, it maintains financial stability through its debt-free status and sufficient cash runway exceeding three years based on current free cash flow. The company's short-term assets significantly surpass its liabilities, indicating sound liquidity management. However, earnings have declined by 10.1% annually over five years and shareholder dilution has been minimal recently amidst stable weekly volatility of 10%.</p>
<div class="lb-trans"><p>Archer Materials Limited 是一家半導體領域的科技公司，預計在 2025 年 6 月結束的財年報告收入為 A$2.8 百萬。儘管處於虧損狀態，淨虧損為 A$6.97 百萬，但通過無債務狀態和基於當前自由現金流超過三年的充足現金流保持財務穩定。公司的短期資產顯著超過其負債，表明流動性管理良好。然而，過去五年中，收益年均下降 10.1%，近期股東稀釋情況較少，周波動性穩定在 10%。</p>
</div><ul>
<li>Take a closer look at Archer Materials' potential here in our financial health report.</li>
<li>Explore historical data to track Archer Materials' performance over time in our past results report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的財務健康報告中更詳細地瞭解 Archer Materials 的潛力。</li>
<li>探索歷史數據，以跟蹤 Archer Materials 隨時間的表現，在我們的過去結果報告中。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9020cb3c-7ddc-42da-92a4-c32aac24964a/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/9020cb3c-7ddc-42da-92a4-c32aac24964a/chart/financial-position-analysis"/></p>
<p>ASX:AXE Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>ASX:AXE 財務狀況分析截至 2025 年 9 月</p>
</div><h2>Peet (ASX:PPC)</h2>
<div class="lb-trans"><h2>Peet (ASX:PPC)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Peet Limited acquires, develops, and markets residential land in Australia with a market cap of A$833.32 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Peet Limited 在澳大利亞收購、開發和銷售住宅用地，市值為 A$833.32 百萬。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from Funds Management (A$56.39 million), Joint Arrangements (A$51.88 million), and Company Owned Projects (A$313.24 million).</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來自資金管理（A$56.39 百萬）、聯合安排（A$51.88 百萬）和公司自有項目（A$313.24 百萬）。</p>
</div><p><strong>Market Cap:</strong> A$833.32M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$833.32M</p>
</div><p>Peet Limited has demonstrated robust financial growth with its earnings increasing by 60% over the past year, surpassing both its five-year average and industry benchmarks. The company's net profit margins have improved, supported by a disciplined strategic approach and favorable market conditions in the Australian residential property sector. Despite high debt levels, Peet's interest payments are well-covered by EBIT, indicating manageable financial obligations. The company is currently undergoing a strategic review led by Goldman Sachs to optimize its asset base and leverage market opportunities further. Recent dividend increases reflect Peet's commitment to returning value to shareholders amidst stable weekly volatility.</p>
<div class="lb-trans"><p>Peet Limited 在過去一年中表現出強勁的財務增長，收益增長了 60%，超過了其五年平均水平和行業基準。公司的淨利潤率有所改善，得益於嚴格的戰略方法和澳大利亞住宅房地產市場的有利條件。儘管債務水平較高，Peet 的利息支付由 EBIT 良好覆蓋，表明財務義務可控。該公司目前正在進行由高盛主導的戰略審查，以優化其資產基礎並進一步利用市場機會。近期的股息增加反映了 Peet 在穩定的周波動性中回饋股東的承諾。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Peet's financial health report.</li>
<li>Review our historical performance report to gain insights into Peet's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Peet 財務健康報告中的詳細發現。</li>
<li>查看我們的歷史業績報告，以獲取 Peet 的業績記錄的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/financial-position-analysis"/></p>
<p>ASX:PPC Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>ASX:PPC 財務狀況分析截至 2025 年 9 月</p>
</div><h2>XRF Scientific (ASX:XRF)</h2>
<div class="lb-trans"><h2>XRF Scientific (ASX:XRF)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries across Australia, Canada, and Europe with a market cap of A$306.01 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> XRF Scientific Limited 在澳大利亞、加拿大和歐洲製造和銷售貴金屬產品、專業化學品和儀器，服務於科學、分析、建築材料和礦業行業，市值為 A$306.01 百萬。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from three main segments: Consumables (A$19.26 million), Precious Metals (A$21.51 million), and Capital Equipment (A$22.56 million).</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來自三個主要部門：消耗品（A$19.26 百萬）、貴金屬（A$21.51 百萬）和資本設備（A$22.56 百萬）。</p>
</div><p><strong>Market Cap:</strong> A$306.01M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$306.01M</p>
</div><p>XRF Scientific Limited has shown consistent financial performance with earnings growing at 20.3% annually over the past five years, though recent growth of 16.9% did not outperform the industry average. The company maintains a strong balance sheet, with short-term assets significantly exceeding both long and short-term liabilities, and debt well-covered by operating cash flow. Despite significant insider selling recently, XRF's management and board are experienced with lengthy tenures averaging over 12 years. Recent inclusion in the S&amp;P Global BMI Index and dividend increases indicate positive market sentiment as net profit margins have improved from last year.</p>
<div class="lb-trans"><p>XRF Scientific Limited 在過去五年中表現出穩定的財務表現，收益年均增長 20.3%，儘管最近的增長 16.9% 未能超過行業平均水平。該公司保持強勁的資產負債表，短期資產顯著超過長期和短期負債，且債務由經營現金流良好覆蓋。儘管近期內部人士大量拋售，XRF 的管理層和董事會經驗豐富，任期平均超過 12 年。最近被納入 S&amp;P 全球 BMI 指數和股息增加表明市場情緒積極，淨利潤率較去年有所改善。</p>
</div><ul>
<li>Dive into the specifics of XRF Scientific here with our thorough balance sheet health report.</li>
<li>Learn about XRF Scientific's future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 XRF Scientific 的詳細資產負債表健康報告。</li>
<li>在這裏瞭解 XRF Scientific 的未來增長軌跡。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/debt-equity-history-analysis"/></p>
<p>ASX:XRF Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月 ASX:XRF 的債務與股本歷史及分析</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Unlock our comprehensive list of 427 ASX Penny Stocks by clicking here.</li>
<li>Searching for a Fresh Perspective? Outshine the giants: these 24 early-stage AI stocks could fund your retirement.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們全面的 427 只 ASX 便士股票列表。</li>
<li>尋找新視角？超越巨頭：這 24 只早期 AI 股票可能為您的退休提供資金。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

三隻市值低於 9 億澳元的 ASX 便士股票值得關注